Suppr超能文献

与高效抗逆转录病毒治疗(HAART)后持续10年病毒载量抑制相关的因素。

Factors associated with 10 years of continuous viral load suppression on HAART.

作者信息

Bello Kathryn J, Mesner Octavio, O'Bryan Thomas A, Won Seung Hyun, Lalani Tahaniyat, Ganesan Anuradha, Agan Brian K, Okulicz Jason F

机构信息

Internal Medicine Service, San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, 78234, TX, USA.

Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, 20814, MD, USA.

出版信息

BMC Infect Dis. 2016 Jul 22;16:351. doi: 10.1186/s12879-016-1677-x.

Abstract

BACKGROUND

The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution and improved HIV outcomes. We studied the factors associated with 10 years of continuous VL suppression on HAART in the US Military HIV Natural History Study.

METHODS

Participants with continuous VL suppression (CS, n = 149) were compared to those who did not have continuous viral load suppression (NCS, n = 127) for ≥10 years on HAART. Factors associated with >10 years of VL suppression were evaluated by multivariate logistic regression. Additionally, association between CS and CD4 reconstitution was analyzed with a mixed effects model.

RESULTS

Compared to NCS participants, a lower proportion of CS participants started HAART in the early HAART era (66 vs 90 %, for years 1996-1999; p < 0.001) and had less antiretroviral use prior to HAART (37 vs 83 %; p < 0.001). At initial HAART, the median CD4 cell count was higher and VL was lower for CS compared to NCS participants (375 cells/uL [256, 499] vs 261 cells/uL [146, 400]; p < 0.001 and 4.4 log10 copies/mL [3.5, 4.9] vs 4.5 log10 copies/mL [3.8, 5.0]; p = 0.048, respectively). New AIDS events were lower during HAART (5 vs 13 %; p = 0.032) and post-HAART CD4 trajectories were greater for the CS compared to NCS group. Factors negatively associated with ≥10 years of VL suppression included log10 VL at first HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) and antiretroviral use prior to HAART (OR 0.16, 95 % CI 0.06, 0.38; p < .001).

CONCLUSIONS

Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the lower proportion of AIDS events observed 10 years after HAART initiation. The current use of more potent and well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by treatment initiated in the early HAART era.

摘要

背景

高效抗逆转录病毒治疗(HAART)的主要目标是持续抑制病毒载量(VL),从而实现免疫重建并改善HIV相关预后。我们在美国军事HIV自然史研究中,对与HAART治疗10年持续病毒载量抑制相关的因素进行了研究。

方法

将持续病毒载量抑制(CS,n = 149)的参与者与未实现持续病毒载量抑制(NCS,n = 127)且接受HAART治疗≥10年的参与者进行比较。通过多因素逻辑回归评估与病毒载量抑制超过10年相关的因素。此外,使用混合效应模型分析CS与CD4重建之间的关联。

结果

与NCS参与者相比,CS参与者中在HAART早期开始治疗的比例较低(1996 - 1999年,分别为66%和90%;p < 0.001),且在HAART治疗前使用抗逆转录病毒药物的比例较低(37%对83%;p < 0.001)。在初始HAART治疗时,CS参与者的CD4细胞计数中位数较高,病毒载量较低,与NCS参与者相比(375个细胞/微升[256, 499]对261个细胞/微升[146, 400];p < 0.001和4.4 log10拷贝/毫升[3.5, 4.9]对4.5 log10拷贝/毫升[3.8, 5.0];p = 0.048)。HAART治疗期间新发艾滋病事件较少(5%对13%;p = 0.032),且与NCS组相比,CS组HAART治疗后的CD4细胞变化轨迹更大。与病毒载量抑制≥10年呈负相关的因素包括首次HAART治疗时的log10病毒载量(比值比0.61,95%置信区间0.4,0.92;p = 0.020)以及HAART治疗前使用抗逆转录病毒药物(比值比0.16,95%置信区间0.06,0.38;p < 0.001)。

结论

持续抑制病毒载量是HIV感染患者长期健康的关键,HAART治疗开始10年后观察到的艾滋病事件比例较低就证明了这一点。目前使用更有效且耐受性良好的治疗方案可能会减轻早期HAART时代开始治疗时所遇到的HAART治疗前病毒载量和既往抗逆转录病毒药物使用的负面因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d7d/4957300/876a10e7840e/12879_2016_1677_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验